AI Article Synopsis
- The study investigates the cost-effectiveness of chemoprophylaxis for preventing symptomatic venous thromboembolism (VTE) after total ankle arthroplasty (TAA), highlighting the lack of extensive research on this topic.
- Researchers analyzed data from 3,455 TAA patients over ten years and conducted a break-even analysis to determine the effectiveness of different medication options such as aspirin, warfarin, enoxaparin, and rivaroxaban based on varying rates of VTE occurrence.
- Findings indicate that while low-dose aspirin and warfarin are generally cost-effective at different VTE rate reductions, enoxaparin and rivaroxaban are only cost-effective at higher initial VTE rates
Article Abstract
Background: Symptomatic venous thromboembolism (VTE) following total ankle arthroplasty (TAA) can cause substantial morbidity and mortality. To prevent this complication, surgeons often prescribe postoperative chemoprophylaxis. However, much controversy exists regarding the efficacy of chemoprophylaxis because of the limited studies exploring its use. Furthermore, even less is known about its cost-effectiveness. Therefore, this study sought to determine the cost-effectiveness of commonly prescribed chemoprophylactic agents using a break-even analysis economic model.
Methods: The literature was searched, and an online database was used to identify patients who developed a symptomatic VTE after undergoing TAA. Our institutional records were used to estimate the cost of treating a symptomatic VTE, and an online drug database was used to obtain the cost of commonly prescribed chemoprophylactic agents. A break-even analysis was then performed to determine the final break-even rate necessary to make a drug cost-effective.
Results: The low and high rates of symptomatic VTE were determined to be 0.46% and 9.8%. From 2011 to 2021, a total of 3455 patients underwent total ankle arthroplasty. Of these patients, 16 developed a postoperative symptomatic VTE (1.01%). Aspirin 81 mg was cost-effective if the initial symptomatic VTE rates decreased by an absolute risk reduction (ARR) of 0.0003% (NNT = 31 357). Aspirin 325 mg was also cost-effective if the initial rates decreased by an ARR 0.02% (NNT = 5807). Likewise, warfarin (5 mg) was cost-effective at all initial rates with an ARR of 0.02% (NNT = 4480). In contrast, enoxaparin (40 mg) and rivaroxaban (20 mg) were only cost-effective at higher initial symptomatic VTE rates with ARRs of 1.48% (NNT = 68) and 5.36% (NNT = 19). Additional analyses demonstrated that enoxaparin (40 mg) and rivaroxaban (20 mg) become cost-effective when costs of treating a symptomatic VTE are higher than our estimates.
Conclusion: Chemoprophylaxis following TAA can be cost-effective. A tailored approach to VTE prophylaxis with cost-effectiveness in mind may be beneficial to the patient and health system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527361 | PMC |
| http://dx.doi.org/10.1177/10711007221112922 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Same-day emergency care: a retrospective observational study of the incidence and predictors of venous thromboembolism following hospital-based acute ambulatory medical care.
J Thromb Haemost
January 2025
Department of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom; Department of Geratology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Background: Same-day emergency care (SDEC) is an expanding area of hospital acute medical care. It aims to minimize delays and manage medical emergency patients within the same day, enabling hospitalization to be avoided; the expectation is that the patients would have required inpatient hospitalization in the absence of the SDEC service. Venous thromboembolism (VTE) prevention is a key medical inpatient safety measure.
View Article and Find Full Text PDFINCREASED CITRULLINATED HISTONE H3 LEVELS AND ACCELERATED THROMBIN KINETICS IN TRAUMA PATIENTS WHO DEVELOP VENOUS THROMBOEMBOLISM.
Shock
December 2024
Division of Trauma, Critical Care, and General Surgery, Department of Surgery, Mayo Clinic, 200 1st St. SW, Rochester, MN, United States 55905.
Background: Neutrophil extracellular traps (NETs), and its formation and release, known as NETosis, may play a role in the initiation of thrombin generation (TG) in trauma. The objective of this study was to assess whether trauma patients, who develop symptomatic venous thromboembolism (VTE), have increased levels of plasma citrullinated histone H3 (CitH3) and accelerated TG kinetics.
Methods: Patients presenting to a Level I Trauma Center as trauma activations had samples collected within 12 hours of time of injury (TOI), alongside healthy volunteers (HV).
Impact of Co-incident Lower Extremity Deep Vein Thrombosis on Symptomatic and Incidental Pulmonary Embolism Outcomes. A Single Center Prospective Cohort Study.
J Thromb Haemost
December 2024
Mayo Clinic, Cardiovascular Medicine - Gonda Vascular Center, Rochester, MN, United States. Electronic address:
Objectives: Study aims were to assess the impact of co-incident lower extremity (LE) deep vein thrombosis (DVT) on clinical outcomes of pulmonary embolism (PE) including venous thromboembolism (VTE) recurrence and mortality.
Methods: Consecutive patients with confirmed acute symptomatic or incidental PE (March 1, 2013 - June 30, 2021) who underwent ultrasound imaging were divided into two groups depending on the presence or absence of LE DVT. Patients were followed prospectively for VTE recurrence, bleeding, and all-cause mortality.
Efficacy of Aspirin in Preventing Venous Thromboembolism in Total Knee and Hip Joint Replacement.
Cureus
November 2024
Orthopedics and Traumatology, Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado, Puebla, MEX.
Background: Venous thromboembolism (VTE) is a significant complication following total knee arthroplasty (TKA) and total hip arthroplasty (THA). Aspirin has gained attention as a cost-effective, safe alternative to traditional anticoagulants like enoxaparin, but comparative data on efficacy and safety remain limited.
Methods: This randomized controlled trial compared the efficacy of aspirin and enoxaparin in preventing VTE following TKA and THA.
Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism - Insights From the COMMAND VTE Registry-2.
Circ J
December 2024
Department of Cardiology, Hirakata Kohsai Hospital.
Article Synopsis
- Previous trials suggest no overall benefit of screening for occult cancer in patients with venous thromboembolism (VTE), but high-risk patients may still benefit.
- A study involving 3,706 patients with acute VTE found that the incidence of newly diagnosed cancer increased over time, reaching 3.7% at one year and 7.0% at three years.
- Factors such as older age, a history of cancer, autoimmune disorders, past major bleeding, and lack of transient VTE risk factors were identified as independent predictors for new cancer diagnoses post-VTE.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!